Representatives of various industries trekked to Annapolis for a marathon hearing on several bills aimed at generating revenue for public education reforms.
Image: Representatives from the Maryland Department of Commerce said getting rid tax credit programs would send a signal that the state is not committed to growing businesses and supporting economic development. BBJ FILE
ROCKVILLE, Md., Feb. 11, 2020 /PRNewswire/ — The Institute for Bioscience and Biotechnology Research (IBBR) is accepting proposals to lease a bio-manufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, proof of concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology (NIST).
Image: https://finance.yahoo.com
NEW BRUNSWICK, N.J., February 11, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.
Image: https://www.jnj.com
Rebecca Stauffer, Parenteral Drug Association Managing Editor posed the following questions to PDA Letter Article readers in fall of 2019. “What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer?”
We invite you to join us for a LIVE and interactive presentation from Jeff Galvin, CEO of American Gene Technologies sharing his passion, vision, and conviction of “reprogramming the human computer.”
Image: https://www.eventbrite.com
With the coronavirus growing more deadly each day, several companies are racing to produce the first vaccine or antiviral medication to combat the spread of the virus. One company that seems to have made large strides towards finding a vaccine, is Gaithersburg-based Novavax.
The genome of the coronavirus was published last month, which opened the floodgates for potential vaccine attempts. Novavax is most notable for releasing an Ebola vaccine within 90 days of the genome being published in 2015, and they estimate they could have a similar timetable for this vaccine as well.
The streets of Wuhan, China — the epicenter of the coronavirus outbreak — are empty and quiet except for the sound of loudspeakers squawking quarantine instructions to its sheltered-in-place residents. Flights to some Chinese cities have been terminated. A Tokyo, Japan-based travel agency has canceled nearly 20,000 of its Chinese package tours.
The World Health Organization (WHO) has declared the coronavirus, which has already killed more people than SARS, a global health emergency. There are currently 11 people stricken with the novel virus in the U.S. and over 17,000 are infected globally with numbers jumping exponentially by the day.
Image: https://biobuzz.io
Citizens across Virginia need health solutions and affordable health care to live full, healthy and productive lives. Lawmakers in the General Assembly are examining a broad range of policies in an attempt to relieve the burden of rising health care costs. But some of the proposals under consideration might have unintended consequences for both patients and Virginia’s innovation economy. As our elected officials consider how to address health care costs, they should ensure that any measure provides meaningful financial relief to patients and preserves the environment for medical innovation in Virginia that delivers groundbreaking treatments and creates thousands of high-paying jobs in the commonwealth.
Image: Kelli Price Photography
I made illustration of Corona virus today. ? I hope scientists and doctors can find a cure soon and I wish everyone who was affected to get well and recover soon! hashtag#sciart
New Members to Add Experience to Board of Directors
ROCKVILLE, MARYLAND, February 12, 2020 – BioHealth Innovation, Inc. (BHI) announced that its Board of Directors unanimously has approved the appointments of six new board members:
“I am privileged to welcome these new members to our board,” said Richard Bendis, BHI President and CEO. “The addition of their leadership experience in the BioHealth Capital Region and beyond ensures in BHI’s ability to have our finger on the pulse of innovation and fresh viewpoints. I also would like to thank Rip Ballou of GSK, Robert Caret of the University System of Maryland, Doug Liu of QIAGEN, Ashish Kulkarni, of Avantor, and Beth Meagher of Deloitte Consulting LLP for their many years of service on our Board of Directors.
Vice President for Health Sciences & Technology, Virginia Tech
Michael Friedlander is the vice president for health sciences and technology at Virginia Tech, where he also serves as the founding executive director of the Fralin Biomedical Research Institute at VTC and the senior dean for research at the Virginia Tech Carilion School of Medicine. He has built the institute’s research programs to over $140 million in current grant value with more than 35 research teams and over 400 investigators and students since its founding in 2010. He has served as the principal investigator on multiple research grants on brain processes that mediate vision, developmental plasticity, and traumatic brain injury. His research has been published in leading journals such as Academic Medicine, Cell, J. Neuroscience, Nature, Neuron, PNAS and Science.
